Thursday, July 9, 2026

pharma · Prostate Cancer · Myelodysplastic Syndromes · SNSE

Sensei Biotherapeutics

Sensei Biotherapeutics clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

ROCKVILLE, MD, USA HQ
2 Employees
Public company Type
SNSE · NYSE Ticker
Company details
Status
Public
HQ
ROCKVILLE, MD, USA
Employees
2
Programs
3
Drugs
0
Patents
1
Intelligence · Clinical Programs

Sensei Biotherapeutics projects

3 ClinicalTrials.gov programs sponsored by Sensei Biotherapeutics.

Sensei Biotherapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. SNS-301

    Sensei Biotherapeutics

    Myelodysplastic Syndromes

    phase 2 small molecule terminated

    1 trial
  2. SNS-301

    Sensei Biotherapeutics

    Squamous Cell Carcinoma of the Head and Neck

    phase 2 small molecule terminated

    1 trial
  3. PAN-301-1

    Sensei Biotherapeutics

    Prostate Cancer

    phase 1 mab completed

    1 trial

Frequently asked questions

How many clinical projects does Sensei Biotherapeutics have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.